You are here

  • Home
  • Archive
  • Volume 12, Issue 6
  • RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Article metrics

Article menu
Oncology
Original research
RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis

 

Online download statistics by month:

Online download statistics by month: June 2022 to April 2025

AbstractFullPdf
Jun 202210191020134
Jul 202224323861
Aug 202224624853
Sep 202237638061
Oct 202244444666
Nov 202232432364
Dec 202215315642
Jan 202312612433
Feb 202314614552
Mar 202313514152
Apr 2023939449
May 2023959635
Jun 2023898928
Jul 202310610939
Aug 202313712946
Sep 202310210231
Oct 202312513142
Nov 202310310739
Dec 202313913438
Jan 2024747132
Feb 202411712046
Mar 202420919592
Apr 202414213957
May 20241079951
Jun 2024928550
Jul 202413712851
Aug 2024126123103
Sep 2024959752
Oct 202411811760
Nov 202412812953
Dec 202411211160
Jan 202515014755
Feb 2025196193111
Mar 202515515898
Apr 202511711976
Total627662432012